SCHEMBL23926520

SCHEMBL23926520

CN(C)C(=O)c1cc2cc(N)cnc2n1C(=O)OC(C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 4/20 0.48
AURKA O14965 3/20 0.48
CCNA2 P20248 2/20 0.35
TTK P33981 2/20 0.35
CDK4 P11802 3/20 0.34
GABRG2 P18507 2/20 0.33
GABRB3 P28472 2/20 0.33
GABRA5 P31644 2/20 0.33
NR1H2 P55055 4/20 0.32
CCND1 P24385 2/20 0.31
GABRA1 P14867 1/20 0.31
GABRA2 P47869 1/20 0.31
GABRA6 Q16445 1/20 0.31
HSP90AA1 P07900 1/20 0.31
HSP90AB1 P08238 1/20 0.31
NR1H3 Q13133 1/20 0.31
JAK3 P52333 1/20 0.31
GPR119 Q8TDV5 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22130320 0.82 CDK4 (0.35) CDK2AURKACDK4CCND1
SCHEMBL23926510 0.82 CDK2 (0.46) CDK2AURKACCNA2TTKCDK4
SCHEMBL22130269 0.81 GABRG2 (0.36) CDK2AURKATTKGABRG2GABRB3
SCHEMBL18181365 0.80 CDK2 (0.47) CDK2AURKACCNA2TTKCDK4
SCHEMBL31349384 0.78 USP2 (0.43)
SCHEMBL23926516 0.76 CDK2 (0.42) CDK2AURKACCNA2TTKCDK4
SCHEMBL13092243 0.73 GABRG2 (0.35) CDK2AURKATTKGABRG2GABRB3
SCHEMBL22130298 0.71 KDR (0.44) NR1H2HSP90AA1HSP90AB1
SCHEMBL5220970 0.69 NOD2 (0.40) GABRG2GABRB3GABRA5
SCHEMBL2875438 0.68 NOD2 (0.37) GABRG2GABRB3GABRA5NR1H2NR1H3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12590071-B2 Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2026-03-31 US disclosed
CN-113727972-B Novel hydrazone derivatives having terminal amine groups substituted with aryl or heteroaryl groups and use thereof 韩国科学技术研究院 2024-12-27 CN disclosed
US-20220396553-A1 NOVEL HYDRAZONE DERIVATIVE IN WHICH TERMINAL AMINE GROUP IS SUBSTITUTED WITH ARYL GROUP OR HETEROARYL GROUP, AND USE THEREOF KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2022-12-15 US disclosed
EP-3901139-A1 NOVEL HYDRAZONE DERIVATIVE WITH ARYL OR HETEROARYL GROUP SUBSTITUTED AT TERMINAL AMINE GROUP THEREOF AND USE THEREOF Korea Institute of Science and Technology (KR) 2021-10-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12590071-B2 Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof ABL1, TH, CYP3A43 CDK2 4016/4885AURKA 2230/4885CCNA2 4786/4885
US-20220396553-A1 NOVEL HYDRAZONE DERIVATIVE IN WHICH TERMINAL AMINE GROUP IS SUBSTITUTED WITH ARYL GROUP OR HETEROARYL GROUP, AND USE THEREOF AANAT, NAT1, HNMT CDK2 2511/4885AURKA 226/4885CCNA2 3713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.